MARSHALL LAUER: Open Payments
NPI 1306800859 · COLLINGSWOOD, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,044 in 93 payments from 17 companies in 2025. Trend: 2023 $1,627 · 2024 $2,206 · 2025 $2,044
Food & beverage: $2,044
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 14 | $561 |
| Novo Nordisk Inc | 12 | $306 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $246 |
| Kowa Pharmaceuticals America, Inc. | 4 | $168 |
| ABBVIE INC. | 11 | $156 |
| Collegium Pharmaceutical, Inc. | 9 | $155 |
| AstraZeneca Pharmaceuticals LP | 7 | $144 |
| Astellas Pharma US Inc | 3 | $68 |
| IDORSIA PHARMACEUTICALS US INC | 2 | $40 |
| Lundbeck LLC | 2 | $36 |
Products named: Kerendia, CAPLYTA, Ozempic, ZORYVE, VRAYLAR, FARXIGA, Belbuca, Veozah.
Industry payments across NJ — which companies pay providers there.
